AGEN1571 for Solid Tumors
This trial is testing a new drug (AGEN1571) to see if it is safe and effective when used alone or in combination with other drugs (balstilimab and/or botensilimab) to treat advanced solid tumors. The trial will be conducted in two parts: (1) a dose escalation phase to determine the recommended phase 2 dose (RP2D) of AGEN1571 and (2) a dose expansion phase to evaluate safety and efficacy in specific disease indications.
- Advanced Solid Tumors
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Has AGEN1571 received authorization from the Federal Drug Administration?
"Limited clinical data exists to support the efficacy and safety of AGEN1571 so it was assigned a score of 1."
Are there still opportunities to partake in this scientific exploration?
"As articulated on clinicaltrials.gov, this experiment is presently seeking out subjects to participate. This project was uploaded onto the database on July 19th 2022 and has since undergone a few modifications as of July 21st 2022."
To what extent is this research being conducted in North America?
"The 8 participating sites for this clinical trial are located in Florida Cancer Specialists (Sarasota, FL), Lifespan Cancer Institute (Providence, RI), USC Norris Comprehensive Cancer Center (Los Angeles, CA) and 6 other medical centres."
To what extent is this research being conducted with participants?
"To successfully execute this trial, 98 volunteers that meet the necessary criteria must be found. Agenus Inc., who is serving as the sponsor of this medical study, will be recruiting these participants from two sites in Florida and Rhode Island respectively."